1. Market Research
  2. > Pharmaceutical
  3. > Drug Delivery Market Trends
  4. > Advanced and Targeted Drug Delivery Market Segmentation, Analysis & Forecast to 2021 Nanoparticles, Polymers, Liposomes, Micelles, Nanoemulsions, Dendrimers, Monoclonal Antibodies by Geography, Therapeutic Area and Stakeholder Environment

Advanced and Targeted Drug Delivery Market Segmentation, Analysis & Forecast to 2021

Nanoparticles, Polymers, Liposomes, Micelles, Nanoemulsions, Dendrimers, Monoclonal Antibodies by Geography, Therapeutic Area and Stakeholder Environment
This newly published report is a global industry analysis on the advanced and targeted drug delivery market that KellySciPub forecasts to grow at a 10.4% CAGR to $319 billion by 2021 from $168 billion today. Supported by over 300 tables and figures, this 382 page report is an extensive industry analysis specifically written for C-Suite, VP and Higher executives within the Pharma and Biotech space.

The advanced and targeted drug delivery market is segmented and analysed through to 2021 with corresponding CAGR breakdown by:

- Technology (Nanoparticles, Polymers (micelles, dendrimers etc), Monoclonal antibodies, Gold nanoparticles-based drug delivery and imaging, Drug eluting stents)
- Geography (Global, USA, Europe, RoW)
- Therapeutic Area (Pulmonary, Ocular drug delivery, Ocular nano-based drug delivery implants, Drug Eluting Stents,
- Sub-Market Analysis (details below)

The monoclonal antibody market is further broken down and presented as the top selling mAbs by company, class and revenue through to 2021 with corresponding CAGR values. Specific figures are given in relation to Humira, Remicade, Avastin, Rituxan, Soliris, Herceptin, Kadcyla, Perjeta, Lucentis, Xgeva/Prolia, Stelara and Tysarbi.

The global market for nano-based targeted drug delivery is presented by the following sub-markets liposomes, polymers (micelles, dendrimers etc) and gold nano-particles through to 2021 with corresponding CAGR figures.
The global pulmonary drug delivery market is analysed and presented as metered dose inhalers (MDIs), dry powder inhalers (DPIs) and nebulizers through 2021 with corresponding CAGR data. This market is also divided into the following geographical regions USA, Europe, RoW, Global through 2021 with corresponding CAGR analysis.

Our PhD analysts identify breakthrough R&D papers and patents and delve into disruptive technical platforms that is revolutionising drug delivery systems. Business, financial and market analysis is performed on all data collated to yield robust figures and forecast through 2021 with CAGR values. Together, our scientific and business team provides you with their in depth knowledge, experience and perspective on the targeted drug delivery landscape. Stake holder analysis of key players including innovators, developers and commercial partners is performed and an in depth chapter of 170 companies involved is presented. The analysis includes details of how is breakthrough technology adoption is changing the drug delivery landscape and also how emerging products like hydrogels, PEGylated phospholipid nanocarriers and cyclodextrins are disrupting conventional markets.

Key Questions Answered in this Report:

- What are the maximum drug release times reported for various nano-based drug carriers?
- What regulatory agencies are approving specific nanomedicines?
- How many liposome-based drugs are available in the market?
- How many stealth liposomes have been granted market approval?
- How many PEGylated liposomes are used for targeted drug delivery?
- Who are the leading players in liposome-based drug formulation?
- What are stimuli-responsive polymers?
- Who are the market leaders in polymer-based drugs?
- What dendrimer-based drugs are the commercially available for targeted delivery?
- What are the applications of inorganic nanoparticles in targeted drug deliver?
- Which companies are focusing on inorganic nanoparticles for targeted drug delivery?
- What are the applications of magnetic nanoparticles in drug delivery, diagnostic and imaging?
- What is the global market value of nanomedicines?
- What is the global market for nanomedicines by therapeutic areas?
- What is the global market for monoclonal antibodies by geography?
- What are the best-selling mAbs?
- What is the global market for major targeted delivery systems?


Table Of Contents

Advanced and Targeted Drug Delivery Market Segmentation, Analysis and Forecast to 2021 Nanoparticles, Polymers, Liposomes, Micelles, Nanoemulsions, Dendrimers, Monoclonal Antibodies by Geography, Therapeutic Area and Stakeholder Environment
TABLE OF CONTENTS

1.0 Introduction 26
1.1 Executive Summary 26
1.2 About this Report 29
1.3 Key Questions Answered in this Report 29
2.0 Targeted Drug Delivery: An Overview 31
2.1 The Need for Targeted Delivery 31
2.2 Advantages and Disadvantages of Targeted Drug Delivery 32
2.3 Types of Drug Targeting 32
2.3.1 Active Targeting 33
2.3.2 Passive Targeting 34
2.3.2.1 Passively Targeted Therapeutic Preparations 35
2.3.2.2 Polymeric Nanoparticles (NPs) Developed for Passive Delivery of Drugs 35
2.4 Ideal Characteristics of Targeted Drug Delivery Carriers 36
2.5 Drug Carriers used in Targeting Systems 37
3.0 Targeted Drug Delivery and Nanomedicines: An Overview 38
3.1 Ideal Characteristics of Nanoparticles suited for Targeted Delivery 38
3.2 Size of Therapeutic Nanoconstructs 38
3.3 Examples of Nanomedicines Approved by One or More Regulatory Bodies 39
3.3.1 Brief Description of Approved Nanomedicines 40
3.3.1.1 Doxil 40
3.3.1.2 Myocet 40
3.3.1.3 DaunoXome 41
3.3.1.4 ThermoDox 41
3.3.1.5 Abraxane 41
3.3.1.6 Rexin-G 42
3.3.1.7 Oncaspar 42
3.3.1.8 Resovist 42
3.3.1.9 Feridex 42
3.3.1.10 Marquibo 42
3.3.1.11 Brentuximab Vedotin (Adectris) 43
3.3.1.12 Trastuzumab Emtansine (Kadcyla) 43
3.3.2 Therapeutic Nanomedicines in Clinical Trials 43
3.4 Targeting Approaches of Nanomedicines 45
3.4.1 Targets of Nanomedicines in the Body 45
3.4.2 Targeting Ligands 46
3.5 Mechanism of Internalization of Nanomedicine 47
3.6 Future Direction of Nanomedicines 47
3.7 Examples of Nanomedicine Applications 48
3.8 Rationale for Nanomedicine Approach 49
3.9 Commercially Available Oral Nanotherapeutics 49
3.10 Commercially Available Nanotherapeutics for Parenteral Administration 50
3.11 Examples of FDA-Approved Nanomedicines for Intravenous Route of Administration 52
3.12 Examples of FDA-Approved Nanomedicines for Pulmonary Route of Administration 52
3.13 Examples of FDA-Approved Nanomedicines for Subcutaneous, Intramuscular, Transdermal and Ocular Route of Administration 53
3.14 Examples of Nano-Based Medical Devices and Diagnostics 54
3.15 Various Types of Nanocarriers Expoited in Formulating Nanomedicines 55
3.15.1 Types of Nanoparticles 56
3.16 Use of Nanoparticles in Different Fields of Medicine 56
3.16.1 Nanosystems for Cancer Treatment 57
3.16.2 Use of Nanosystems in Tissue Engineering 58
3.16.3 Use of Nanoparticles (NPs) in Stem Cell Therapy 59
3.16.4 Use of Nanoparticles in Contrast Agents 59
3.17 Segmentation of Targeted Drug Delivery Nanosystems 60
4.0 Lipid-Based Targeted Drug Delivery Nanosystems 61
4.1 Advantages and Disadvantages of Liposomes as Targeted Drug Delivery Systems 61
4.2 Classification of Liposomes on the Basis of Size and Composition 62
4.2.1 Classification of Liposomes on the Basis of Method of Preparation 63
4.3 Size of Liposomes 63
4.4 New Generation of Liposomes and their Features 63
4.5 Conventional Liposomes 64
4.5.1 Benefits of Drug Loads in Liposomes 65
4.5.2 Loading Liposomes with Drugs 65
4.5.3 Intracellular Delivery of Drugs by Liposomes 66
4.5.4 Liposome-Based Drugs in the Market 67
4.5.5 Liposome-Based Drugs for Cancer Therapy 68
4.5.6 Liposomal Drugs in Clinical Trial 69
4.6 Modified Liposomes 70
4.6.1 Stealth Liposomes 71
4.6.1.1 Approved Stealth Liposomes 72
4.7 Targeted Liposomes 72
4.7.1 Stimuli-Sensitive Targeted Liposomes 73
4.7.2 Targeted Liposomal Drugs for Cancer 74
4.8 Technology Developments in Lipid-Based Carriers 75
4.9 Key Players Focusing on Lipid-Based Carriers 75
5.0 Polymer-Based Carriers for Targeted Drug Delivery 76
5.1 Stimuli-Responsive or Smart Polymers 76
5.1.1 Temperature-Responsive Polymers 78
5.1.1.1 Classification of Thermosensitive Polymers 78
5.1.2 PH-Sensitive Polymers 79
5.1.3 Bioresponsive Polymers 80
5.1.4 Field-Responsive Polymers 80
5.2 Polymer-Based Topical Delivery Systems for Dermatological Diseases 81
5.2.1 Natural Polymer-Based Topical Delivery Systems 81
5.2.2 Topical Delivery Systems Based on Synthetic Polymeric Particles 81
5.3 Clinical Status of Polymeric Nanoparticles in Cancer Treatment 82
5.4 Polymeric Nanoparticle-Based Therapeutics in Clinical Trials 83
5.5 Key Players Focusing on Polymer-Based Carriers 84
6.0 Polymeric Micelle/Co-Polymers for Targeted Drug Delivery 85
6.1 Substances used to produce Micelle and their Drug Release Duration 85
6.2 Existing Approaches to Achieve Sustained Release from Micelle 86
6.2.1 Stimulai-Responsive Micelles 88
6.3 Passive Targeting of Polymeric Micelle 88
6.4 Active Targeting of Polymeric Micelle 89
6.5 Stimuli-Responsive Polymeric Micelles 91
6.6 Multifunctional Polymeric Micelles 93
6.6.1 Examples of Multifunctional Drug-Loaded Micelle 93
6.6.2 Multifunctional Micelles for the Delivery of siRNA 94
6.7 Drug-Loaded Polymeric Micelle-Based Products in Development 95
7.0 Dendrimer-Based Targeted Drug Delivery 97
7.1 Three-Dimensional Structure of Dendrimers 97
7.2 Dendrions as Multifunctional Nanoplatforms 97
7.3 Commercially Available and Late-Stage Dendrimers 98
7.4 Therapeutic Moieties studied using Dendrimer Platform 99
7.5 Thermosensitive Dendrimers 100
8.0 Inorganic Nanoparticles for Targeted Drug Delivery 102
8.1 Companies Focusing on Inorganic Nanoparticles 102
8.2 Carbon-Based Nanoparticles for Drug Delivery 102
8.2.1 Carbon Nanotubes (CNTs) 103
8.2.1.1 Structure of Carbon Nanotubes 104
8.2.1.2 Artificial Implants from Carbon Nanotubes (CNTs) 104
8.2.1.3 Detection of Cancer Biomarker by Carbon Nanotubes 105
8.2.1.4 Drug and Gene Delivery by Carbon Nanotubes 106
8.3 Fullerenes 106
8.3.1 Structure of Fullerene 106
8.3.2 Biomedical Applications of Fullerenes 107
8.4 Graphine Oxide (GO) as Nanocarriers 108
8.4.1 GO for Drug Delivery 109
8.5 Gold-Based Nanoparticles (AuNPs) 109
8.5.1 Shapes of Gold Nanoparticles 110
8.5.2 Imaging Applications of Gold Nanoparticles 110
8.5.3 Drug Delivery Applications of Gold Nanoparticles 111
8.5.4 Diagnostic Applications of Gold Nanoparticles 111
8.6 Silica Nanoparticles for Drug Delivery 112
8.6.1 Types of Silica Nanoparticles 112
8.6.2 The Process of Synthesis of SNs 113
8.6.3 Drugs Delivered through Silica Nanoparticles 114
8.7 Magnetic Particles for Drug Delivery 115
8.7.1 Companies Focusing on Magnetic Particles 115
8.7.2 Typical Design of a Magnetic Nanoparticle 115
8.7.3 Use of Magnetic Nanoparticles 116
8.7.4 Diagnostic Use 116
8.7.5 Coating Materials for Magnetic Nanoparticles 117
8.7.6 Organic Linkers in Magnetic Nanoparticles 117
8.7.7 Targeted Magnetic Nanoparticles (MNPs) as Cancer Theranostics 118
8.7.8 Targeting Magnetic Nanoparticles to Tumors (Passive and Active) 118
8.7.9 Magnetic Nanoparticles as Diagnostics 119
8.7.10 Magnetic Nanoparticles as Multimodal Imaging Agents 120
8.7.11 FDA/EMEA Approved Magnetic Nanoparticle-Based Cotrast Agents 120
9.0 Cell-Based Systems for Targeted Delivery 122
9.1 Companies Focusing on Cell-Based Carriers 122
9.2 Role of Dendritic Cells (DCs) in Drug Delivery 122
9.3 Engineered RBCs for Drug Delvery 124
9.3.1 Therapeutic Sites and Targets Accessible for RBC-Delivered Drugs 124
9.3.2 Examples of Therapeutic Enzymes Encapsulated in Carrier RBCs 125
9.4 Stem Cells for Drug Delivery 125
9.5 Bacterial Ghosts for Drug Delivery 126
10.0 Nucleic Acid/Peptide as Drug Carriers 127
10.1 `Companies Focusing on Aptamers/Nucleic Acids/Peptides 127
10.2 Peptide Conjugates for Drug Delivery 127
10.2.1 Peptides as Radfionuclide Carriers 128
10.2.3 Peptide Hormones 129
10.2.4 Peptide Vaccines 129
10.2.5 Peptide as Cytotoxic Drug Carrier 130
10.2.6 Cell-Penetrating Peptides 131
10.2.7 Peptides Applied in Cancer Diagnostics 131
10.2.8 Peptides Applied in Treating Cancer 132
10.2.9 Peptide-Based Vaccines in Clinical Development 133
10.3 DNA/RNA Aptamers 133
10.3.1 Clinical Use of Aptamers 134
10.4 DNA Origami (DNA Nanorobots) 135
11.0 Targeted Therapies by Indication: An Overview 136
11.1 Targeted Cancer Therapies 136
11.1.1 Identification of Targets in Cancer Therapy 137
11.1.2 Categories and Examples of Tumor Antigens 137
11.1.3 Development of Targeted Therapies for Cancer 139
11.1.4 Targeted Cancer Therapies in Late Stage Development 140
11.1.5 Companies Focusing on Oncology Applications of Targeted Drug Delivery 140
11.2 Monoclonal Antibodies (mAbs) and Targeted Drug Delivery 141
11.2.1 Monoclonal Antibodies (mAbs) 141
11.2.1.1 Naked mAbs 142
11.2.1.2 Examples of Naked mAbs and their Fuctions 142
11.2.1.3 Conjugated mAbs 143
11.2.1.4 Bispecific mAbs 145
11.2.2 U.S./E.U.-Approved mAbs 146
11.2.3 mAbs by Indication Area 147
11.2.4 mAb Biosimilars in Late Stage Development 147
11.2.5 Biosimilar mAbs in Development 148
11.3 Ocular Applications of Targeted Drug Delivery 148
11.3.1 Ocular Applications of Dendrimer Systems 149
11.3.2 Ocular Applications of Liposomes 150
11.3.3 Micelles in Ocular Drug Delivery 151
11.3.3.1 Micelle Systems Investigated for Ocular Drug Delivery 151
11.3.4 Viral and Non-Viral Vectors for Ocular Gene Delivery 152
11.4 Targeted Drug Delivery for Central Nervous System (CNS) Disorders 153
11.4.1 Blood Brain Barrier (BBB) 153
11.4.2 Drug Delivery Approaches and Drug Molecules for Brain 154
11.4.3 Examples of Nanoparticles (NPs) used for Delivery of Drugs across BBB 155
11.4.4 Examples of Clinically-Approved NPs Therapeutics for CNS Disorders 155
11.4.5 Dendrimers for CNS Drug Delivery 156
11.5 Infectious Disease Applications for Targeted Drug Delivery 157
11.5.1 Liposomes for Antimicrobial Drug Delivery 157
11.5.2 Polymeric Nanoparticles for Antimicrobial Drug Delivery 158
11.5.3 Solid Lipid Nanoparticles (SLNs) for Antimicrobial Drug Delivery 159
11.5.4 Dendrimers for Antimicrobial Drug Delivery 160
11.6 Cardiovascular Applications for Targeted Drug Delivery 160
11.6.1 Nanoparticles for Advanced Diagnostics and Therapy of Cardiovascular Diseases 161
11.6.2 Therapeutic and Theranostic Nanoparticles for CVD 161
11.6.3 In vivo Nanosensors for CVD 162
11.7 Targeted Drug Delivery for Pulmonary Diseases 163
11.7.1 Drugs for Inhalation 163
11.7.2 Polymers for Colloidal Pulmonary Drug Delivery Systems 164
11.7.3 Nebulizers with Novel Technologies for Pulmonary Drug Delivery 166
11.7.4 Novel Dry Powder Inhalers (DPIs) 166
11.7.5 Types of Nanoparticles used to Encapsulate API Molecules 167
11.8 Cosmeceutical Applications of Nano-Based Drugs for Targeted Delivery 168
12.0 Other Targeted Drug Delivery Technologies 170
12.1 Ocular Implants 170
12.1.1 Ocular Implants under Clinical Development 170
12.1.2 FDA-Approved Ocular Drug Delivery Implants 171
12.1.3 Sustained Trans-Scleral Ocular Drug Delivery 172
12.2 Drug Eluting Stents (DES) and Targeted Drug Delivery 173
12.2.1 Polymers for Stent Coatings 173
12.3 Microchips: The Novel Implantable Drug Delivery Technology 174
13.0 Market Analysis to 2021 176
13.1 Applications of Nanoparticles in Healthcare 176
13.2 Types of Nanomedicine Companies 177
13.3 Global Market for Nanomedicines to 2021 177
13.3.1 Nanomedicines Market by Major Therapeutic Area 178
13.4 Global Market for Targeted Drug Delivery to 2021 180
13.4.1 Global Market for mAbs to 2021 182
13.4.1.1 Best-Selling mAbs 2014-2021 183
13.4.1.2 Global Market for Humira, Remicade and Avastin 183
13.4.1.3 Global Market for Rituxan, Soliris and Herceptin 184
13.4.1.4 Global Market for Kadcyla, Perjeta and Lucentis 185
13.4.1.5 Global Market for Xgeva/Prolia, Stelara and Tysarbi 186
13.5 Global Market for Nanoparticle-Based Targeted Drug Delivery Systems to 2021 187
13.6 Ocular Drug Delivery Market to 2021 188
13.6.1 Novel Ocular Drug Delivery Systems 189
13.6.1.2 Ocular Drug Delivery Implants 190
13.7 Global Market for Implanted Drug Eluting Stents to 2021 192
13.8 Pulmonary Drug Delivery to 2021 193
13.9 What does the Future hold for the Targeted Drug Delivery Market? 195
13.10 Impact of New Technology Systems on the Current Targeted Delivery Market 196
13.11 Future Directions in Drug Delivery 197
13.12 Disruptive Technologies within the Existing Targeted Delivery Market 197
13.12.1 Emergence of Hydrogels in Oral Drug Delivery 197
13.12.2 Emergence of PEGylated Phospholipid Nanocarriers for Respiratory Diseases 198
13.12.3 Emergence of Cyclodextrins 199
13.12.3.1 Cyclodextrins in Oral Drug Delivery 199
13.12.3.2 Cyclodextrins in Rectal Drug Delivery 200
13.12.3.3 Cyclodextrin in Nasal Drug Delivery 200
13.12.3.4 Cyclodextrins in Transdermal Drug Delivery 200
13.12.3.5 Cyclodextrins in Ocular Drug Delivery 201
13.12.3.6 Cyclodextrins in Controlled Drug Delivery 201
14.0 Selected Company Profiles 203
14.1 3M Company 203
14.1.1 3M Drug Delivery Systems 203
14.2 Abbott Laboratories 203
14.2.1 Gengraf 203
14.2.2 Kaletra 204
14.2.3 Norvir 204
14.3 Ablynx NV 204
14.3.1 Nanobody Technology 204
14.3.2 Clinical Programs 205
14.3.3 Ablynx's Partnership with Boehringer Ingelheim 205
14.3.4 Ablynx's Partnership with Eddingpharm 206
14.3.5 Ablynx's Partnership with Genzyme 206
14.3.6 Ablynx's Partnership with Merck and Co. 206
14.3.7 Ablynx's Partnership with Merck KGaA 206
14.3.8 Ablynx's Partnership with Novartis 206
14.3.9 Ablynx's Partnership with Taisho Pharmaceutical 207
14.4 Aciont Inc. 207
14.4.1 Visulex Technology 207
14.5 Acrux 208
14.5.1 Patchless Patch 208
14.5.2 Axiron 208
14.5.3 Evamist and Lenzetto 208
14.6 Agilis Biotherapeutics LLC 209
14.6.1 Agilis' Engineered DNA Therapeutics 209
14.6.2 Agilis' DNA Therapeutic Programs 209
14.6.2.1 DNA Therapeutics for Friedreich's Ataxia 209
14.6.2.2 DNA Therapeutics for Angelman Syndrome (AS) 209
14.7 Aileron Therapeutics Inc. 210
14.7.1 P53 Pathway Re-Activator 210
14.8 Alchemia Oncology Pty Ltd. 211
14.8.1 HA-Irinotecan 211
14.8.2 HA-Doxorubicin (Hyaluronic acid + Doxorubicin) 211
14.8.3 HA-5-Fluorouracil (Hyaluronic acid + 5-Fluorouracil) 211
14.8.4 Monoclonal Antibodies 212
14.9 Alkermes Pharma Ireland Ltd. 212
14.9.1 Aristada 212
14.9.2 Vivitrol 212
14.9.3 U.S. Products using Alkermes' Technologies 213
14.9.3.1 Bydureon 213
14.9.3.2 Ampyra 213
14.9.3.3 Risperdal Consta 213
14.9.3.4 Invega Trinza 213
14.9.4 Alkermes' Long-Acting Technologies 214
14.9.4.1 Medisorb Technology 214
14.9.4.2 LinkeRx Technology 214
14.9.4.3 NanoCrystal Technology 214
14.10 Allergan Inc. 214
14.10.1 Doryx (Delayed-Release Tablets) 215
14.10.2 Saphris (Sub-Lingual Tablets) 215
14.10.3 Namenda XR (Extended Release Capsules) 215
14.10.4 Namzaric (Extended Release Capsule) 215
14.10.5 Asacol HD (Delayed-Release Tablets) 215
14.10.6 Delzicol (Delayed-Release Tablets) 215
14.10.7 Zenpep (Delayed-Release Tablets) 215
14.11 Alnylam Pharmaceuticals 216
14.11.1 Development Pipeline 216
14.11.2 Strategic Alliances 216
14.12 AmpliPhi Biosciences 217
14.12.1 Product Pipeline 217
14.13 Andros Pharmaceuticals Co., Ltd. 217
14.13.1 High-End Cosmetic Ingredient 218
14.13.2 Topical Drug Delivery System 218
14.13.3 Gene Delivery System 218
14.14 Angiochem Inc. 219
14.14.1 LRP-1 Technology 219
14.15 Antares Pharma Inc. 220
14.15.1 VIBEX 220
14.15.2 Pen Injectors 220
14.15.3 Partnered Products 221
14.16 Aposense Ltd. 221
14.16.1 Apo-si 221
14.16.2 ATT-11T 221
14.16.3 F-ML-10 222
14.16.4 ATT-LD 222
14.17 Applied Genetic Technologies Corp. (AGTC) 222
14.17.6 Technology 222
14.18 Aptagen LLC 223
14.18.1 Apta-Services (RandD Support) 223
14.18.2 Apta-Index 223
14.19 Aradigm Corp. 224
14.19.1 Technology 224
14.19.2 Aradigm's Product Pipeline 224
14.20 ArisGen SA 225
14.20.1 ArisCrown Technology 225
14.20.2 Sublingual Exenatide ARG011 226
14.21 Armagen Technologies Inc. 226
14.21.1 Armagen's Technology 226
14.21.2 Armagen's Licensing and Collaboration Agreement with Shire 227
14.21.3 Armagen's Partnership with PacificGMP 227
14.22 Arrowhead Research Corp. 228
14.22.1 Arrowhead's Lead Products 228
14.22.2 The Dynamic Polyconjugate Platform 228
14.23 Artificial Cell Technologies Inc. 229
14.23.1 Technology 229
14.23.2 Respiratory Syncytial Virus (RSV) Vaccine 229
14.23.3 Malaria Vaccine 229
14.24 AsclepiX Therapeutics LLC 230
14.24.1 Anti-Angiogenesis Therapy 230
14.25 Asklepios BioPharmaceutical Inc. 230
14.25.1 Asklepios' Collaboration with Baxter 231
14.25.2 Asklepios' Collaboration with Medtronic 231
14.25.3 Asklepios' Collaboration with ALS Therapy Development Institute 231
14.25.4 Asklepios' Collaboration with Genzyme 231
14.25.5 Asklepios' Collaboration with Pfizer 232
14.26 Astellas Pharma Inc. 232
14.26.1 AmBisome 232
14.27 Audentes Therapeutics Inc. 232
14.27.1 Technology 232
14.28 Avalanche Biotechnologies Inc. 233
14.28.1 The Ocular BioFactory Platform 233
14.29 Avita Medical Ltd. 234
14.29.1 ReCell FOR Burns and Plastics 234
14.29.2 ReCell for pigmentation 234
14.29.3 ReCell for Chronic Wounds 234
14.29.4 Funhaler 234
14.29.5 Breath-A-Tech 235
14.30 Azaya Therapeutics Inc. 235
14.30.1 Products 235
14.31 Bachem Americas Inc. 235
14.31.1 API Products 235
14.32 Bayer Pharma AG 236
14.32,1 Cipro 236
14.33 BBB Therapeutics BV 236
14.33.1 G-Technology 236
14.33.2 Product Pipeline 237
14.34 Bespak Europe Ltd. 238
14.34.1 Inhalation Delivery Devices 238
14.34.2 Injectable Drug Delivery Devices 238
14.34.3 VapourSoft Technology 238
14.34.4 ASI Technology 239
14.35 Bicycle Therapeutics Ltd. 239
14.35.1 Bicycle Molecules 239
14.35.2 R and D in Oncology 239
14.35.3 R and D in Ophthalmology 239
14.36 BigDNA Ltd. 240
14.36.1 Technology 240
14.37 BIND Therapeutics Inc. 240
14.37.1 Accurins 241
14.37.2 BIND Therapeutics' Intellectual Property 241
14.37.3 BIND's Collaboration with Pfizer 242
14.37.4 BIND's Collaboration with Merck 243
14.38 BioDelivery Sciences International Inc. 243
14.38.1 BEMA Technology 243
14.38.2 Onsolis 243
14.38.3 Belbuca (Buprenorphine HCL Buccal Film) 243
14.38.4 Bunavail 243
14.38.5 Clonidine Topical Gel 244
14.39 Bioject Medical Technologies Inc. 244
14.39.1 Technology 244
14.39.2 Biojector 2000 244
14.39.3 Bioject Zetajet 245
14.39.4 Biojet Drug Reconstitution System 245
14.39.5 Needle-Free Vial Adapter 245
14.40 BioZone Laboratories Inc. 245
14.40.1 QuSomes Technology 245
14.40.2 LipoSpray Technology 245
14.40.3 Ela-Max 246
14.41 Camurus AB 246
14.41.1 Technologies 246
14.41.1.1 FluidCrystal Injection Depot 246
14.41.1.2 FluidCrystal Topical Bioadhesive 246
14.41.1.3 FluidCrystal Nanoparticles 246
14.41.1.4 CAM2029 247
14.41.1.5 CAM2038 247
14.41.1.6 CAM2038 (Chronic Pain) 247
14.41.1.7 CAM2032 247
14.41.1.8 Episil Oral Liquid 248
14.42 Celsion Corp. 248
14.42.1 Celsion's LTLD Technology 248
14.42.2 Celsion's Pipeline 249
14.43 CeramiSphere Pty Ltd. 249
14.43.1 Technology 249
14.43.1.1 Mucosal Delivery of Proteins 250
14.43.1.2 Delivery of DNA and RNA 250
14.43.1.3 Delivery of Wound Healing Drugs 250
14.44 Cerulean Pharma Inc. 250
14.44.1 Nanoparticle-Drug Conjugates (NDCs) 250
14.45 Chrysalis BioTherapeutics Inc. 251
14.45.1 Radiation Therapy (TP508) 252
14.45.2 Solution for Nuclear Emergencies 252
14.45.3 Solution for Cardiovascular Disease 252
14.45.4 Solution for Regenerative Medicine 252
14.46 Copernicus Therapeutics Inc. 253
14.46.1 Technology 253
14.47 Cornerstone Pharmaceuticals Inc. 254
14.47.1 AEMD Platform 254
14.47.2 Emulsiphan Pipeline 254
14.48 CureVac AG 254
14.48.1 CureVac's RNA Technology Platforms 255
14.49 CytImmune Sciences Inc. 256
14.49.1 Aurimune 256
14.49.2 CYT-6091 256
14.49.3 CYT-21000 256
14.49.4 Partnership with Coldstream Laboratories Inc. 256
14.50 DepoMed Inc. 257
14.50.1 Acuform Technology 257
14.50.2 Products 257
14.50.2.1 Nucynta ER 257
14.50.2.2 Cambia 257
14.50.2.3 Lazanda 257
14.50.2.4 Zipsor 258
14.51 Dicerna Pharmaceuticals 258
14.51.1 DsiRNA-EX-Conjugate technology 258
14.51.2 EnCore Lipid Nanoparticles 258
14.52 Dimension Therapeutics Inc. 259
14.52.1 Engineered AAV Vectors 259
14.52.2 Hemophilia Program 259
14.52.3 Ornithine transcarbamylase (OTC) deficiency 259
14.52.4 Glycogen Storage Disease Type Ia (GSDIa) 259
14.53 Dipexium Pharmaceuticals Inc. 260
14.53.1 Locilex 260
14.54 Discovery Laboratories Inc. 260
14.54.1 AEROSURF - Aerosolized KL4 Sulfactant 260
14.54.2 KL4 Sulfactant 261
14.54.3 Capillary Aerosol Generator (CAG) Technology 261
14.55 DURECT 261
14.55.1 Technologies 262
14.55.1.1 Epigenomic Regulator Program 262
14.55.1.2 Long-Acting Injectables 262
14.55.1.3 Abuse Deterrant Technology 262
14.55.1.4 Transdermal Technology 262
14.55.2 Patents 262
14.55.3 Products in Development 262
14.55.3.1 DUR-928 262
14.55.3.2 POSIMIR 263
14.55.3.3 REMOXY 263
14.55.3.4 ORADUR 263
14.55.3.5 ORADUR - Methylphenidate 263
14.55.3.6 RELDAY 263
14.55.3.7 ELADUR 263
14.55.4 Commercial Products 264
14.55.4.1 ALZET Osmotic Pumps 264
14.55.4.2 LACTEL 264
14.56 EnGeneIC Ltd 264
14.56.1 EDV Nanocells 265
14.56.2 Completion of Series B Financing 265
14.56.3 2015 Thomson Reuters Award 265
14.56.4 EnGeneIC's Phase I Clinical Study for Advanced Glioma Patients 266
14.57 Ensysce Biosciences Inc. 266
14.57.1 Single-Walled Carbon Nanotubes (SWCNT) 266
14.57.2 Ensysce's Product Pipeline 266
14.58 EryDel SpA 267
14.58.1 Technology 267
14.58.2 EryDex System 268
14.59 EryTech Pharma 268
14.59.4 ERY-ASP (GRASPA) 268
14.59.5 EryTech's Key Corporate Facts 269
14.59.6 Deloitte Award 270
14.60 Esperance Pharmaceuticals Inc. 270
14.60.1 MDPs Technology 270
14.60.2 Pipeline 270
14.61 Exicure Inc. 271
14.61.1 SNA Platform 271
14.62 FIT Biotech Oy 272
14.62.1 Gene Transfer Unit (GTU) Platform 272
14.63 Flamel Technologies S.A. 272
14.63.1 Flamel's Drug Delivery Platforms 272
14.63.2 Micropump 273
14.63.3 LiquiTime 273
14.63.4 Trigger Lock 273
14.63.5 Medusa 273
14.64 Generex Biotechnology Corp. 273
14.64.1 RapidMist Technology 274
14.64.2 Antigen Express Technology 274
14.64.3 Generex Oral-Lyn 274
14.65 Genetic Immunity Inc. 274
14.65.1 DermaVir 275
14.65.2 Technology 275
14.64.2.1 DermaPrep 275
14.64.2.2 ANTIGENeering 275
14.64.2.3 Nanomedicine 275
14.65 Genus Pharmaceuticals Ltd. 275
14.65.1 Fenogal 275
14.66 GenVec Inc. 276
14.66.1 AdenoVerse Technology 276
14.67 GlaxoSmithKline LLC 277
14.67.1 Adavir Diskus 277
14.67.2 Sustiva 277
14.67.3 Agenerase 277
14.68 Glide Pharmaceutical Technologies Ltd. 278
14.68.1 Technologies 278
14.69 Heron Therapeutics Inc. 279
14.69.1 Biochronomer Technology 279
14.69.2 Sustol 280
14.69.3 HTX-019 280
14.69.4 HTX-011 280
14.70 Hoffmann-LaRoche Inc. 280
14.70.1 Fortovase 280
14.71 ICB International Inc. 281
14.71.1 Platform Technology 281
14.72 iCeutica Inc. 281
14.72.1 Product Pipeline 282
14.72.2 SoluMatrix Technology 283
14.73 ImmusanT Inc. 283
14.74 InDex Pharmaceuticals AB 284
14.74.1 Kappaproct 284
14.75 Immune Design 285
14.76 Immunocore Ltd. 285
14.76.1 ImmTACs 286
14.77 Inovio Pharmaceuticals 286
14.77.1 SynCon Technology 286
14.78 Insite Vision Inc. 287
14.78.1 DuraSite Technology 287
14.79 Insmed Inc. 288
14.80 Intezyne Technologies Inc. 289
14.80.1 IVECT Method 289
14.80.2 Intezyne's Pipeline 290
14.81 Keystone Nano Inc. 290
14.81.1 NanoJacket Technology 290
14.81.2 NanoLiposome Technology 290
14.82 Kowa Pharmaceuticals America Inc. 291
14.82.1 Livalo 291
14.82.2 Lipofan 291
14.83 LipimetiX Inc. 291
14.83.1 Technology 292
14.84 LiPlasome Pharma ApS 292
14.84.1 LiPlasome's Pipeline 292
14.84.2 LiPlaCis 293
14.85 Lipocine Inc. 293
14.85.1 LCPN 1021 293
14.85.2 LCPN 1111 293
14.85.3 LPCN 1107 294
14.85.4 Lip'ral Technology 294
14.86 Lipotek Pty Ltd. 295
14.86.1 Technology 295
14.87 Living Cell Technologies Ltd. 296
14.87.1 DIABECELL 296
14.87.2 NTCELL 296
14.88 Madison Vaccines Inc. 296
14.88.1 Technology 297
14.89 MagForce AG 297
14.89.1 NanoTherm Therapy 297
14.89.2 NanoTherm 298
14.89.3 NanoPlan 298
14.89.4 NanoActivator 298
14.90 Mankind Pharma Ltd. 298
14.90.1 Technosphere Technology 298
14.91 Mersana Therapeutics Inc. 299
14.91.1 Fleximer Platform 299
14.91.2 Dolaflexin 299
14.91.3 Mersana's Partnership with Takeda 300
14.91.4 Mersana's Partnership with EMD Serono 300
14.91.5 Mersana's Partnership with Recepta Biopharma S.A. 300
14.92 Micochips Biotech Inc. 300
14.92.1 Technology 300
14.92.2 Applications 301
14.92.3 Current Partnerships 301
14.92.3.1 Teva Pharmaceuticals 301
14.92.3.2 Gates Foundation 301
14.93 Milo Biotechnology LLC 301
14.93.1 Technology 302
14.94 miRagen Therapeutics Inc. 302
14.95 Mirna Therapeutics Inc. 303
14.95.1 Technology 303
14.95.2 MRX34 303
14.96 Miros Polymers Inc. 303
14.96.1 Technology 304
14.96.2 Drug Delivery Systems 304
14.96.2.1 ExCell 304
14.96.2.2 PolyGel 304
14.97 Moderna Therapeutics Inc. 304
14.97.1 mRNA Expression Platform 305
14.98 MultiVir Inc. 305
14.98.1 MultiVir's Product Candidates 305
14.99 Mystic Pharmaceuticals Inc. 306
14.99.1 VersiDoser Delivery Platform 306
14.99.2 VRx2 Delivery Platform 306
14.99.3 Intranasal Delivery Systems 306
14.99.4 Nose to Brain Delivery Systems 307
14.99.5 Ophthalmic Delivery Systems 307
14.99.6 Sublingual Delivery Systems 307
14.100 Nanobiotix 307
14.100.1 NanoXray 307
14.101 Nanocarrier Co., Ltd. 308
14.101.1 Micellar Nanoparticles 308
14.102 Nanocopoeia Inc. 309
14.102.1 ElectroNanospray (ENS) Process 309
14.103 NanoMedical Systems Inc. 310
14.103.1 Personalized Molecular Drug Delivery System (PMDS) 310
14.103.2 NanoMedical Diagnostics (NMD) 310
14.103.3 Multi-Stage NanoVector Drug Delivery System (MSV) 310
14.104 NanoOncology Inc. (PeptiMed Inc.) 311
14.104.1 NanoOncology's Product Pipeline 311
14.104.2 Ovarian Cancer Program 311
14.104.3 Breast Cancer Program 312
14.104.4 Lung Cancer Program 312
14.105 Nanospectra Biosciences Inc. 312
14.105.1 AuroLase Therapy 312
14.106 Nano Precision Medical Inc. 313
14.106.1 The NanoPortal Solution 313
14.107 Nanotherapeutics Inc. 313
14.108 nanoTherics Ltd 314
14.108.1 magneTherm 315
14.108.2 Live Cell Alternating Magnetic Field Exposure System (LC-AMF System) 315
14.108.3 Magnefect System 315
14.109 NanoVector Inc. 315
14.109.1 Product Strategy 315
14.109.2 NVI-9010 316
14.110 NanoViricides Inc. 316
14.110.1 Platform Technology 316
14.111 Nektar Therapeutics 317
14.111.1 Technology 317
14.112 Neos Therapeutics Inc. 318
14.112.1 Proprietary Technology 319
14.112.2 Rapidly Disintegrating Ionic Masking 319
14.112.3 Dynamic Time Release Suspension 319
14.112.4 Kinetically Controlled Tamper Protection 320
14.112.5 Currently Marketed Product 320
14.113 NeXstar Pharmaceuticals Inc. 320
14.113.1 DaunoXome 320
14.114 NightstaRx Ltd. 321
14.114.1 AAV2-REP1 321
14.115 NOD Pharmaceuticals Inc. 321
14.115.1 Technology 321
14.115.1.1 Nodlin 322
14.115.1.2 Nodexen 322
14.116 Nordic Nanovector ASA 322
14.116.1 Antibody-Radionucleotide-Cojugate 322
14.116.2 Betalutin 322
14.117 Novagali Pharma S.A. 323
14.117.1 Novasorb Technology 323
14.118 Novartis Pharmaceuticals Corp. 324
14.118.1 Neoral 324
14.119 Ocular Therapeutix Inc. 324
14.119.1 ReSure Sealant 324
14.119.2 Dextenza 325
14.119.3 Sustained Release Travoprost 325
14.119.4 Posterior Segment Injections 325
14.120 Oncolytics Biotech Inc. 325
14.120.1 Reolysin 325
14.121 Oxford Biomedica plc 326
14.121.1 OXB-201 (RetinoStat) 326
14.121.2 SAR 422459 326
14.121.3 SAR 421869 326
14.121.4 EncorStat 326
14.121.5 OXB-102 326
14.121.6 MoNuDin 327
14.121.7 OXB-301 (TroVax) 327
14.121.8 Anti-5T4 Antibody 327
14.121.9 The LentiVector Platform 327
14.121.10 5T4 Tumor Antigen 327
14.121.11 CAR-T Cell Therapy 327
14.122 PDS Biotechnology Corp. 328
14.122.1 Versamune NanoPlatform- 328
14.123 PharmaIN Corp. 329
14.123.1 Protected Graft Copolymer (PGC) 329
14.124 PhaseRx Inc. 330
14.124.1 mRNA Technology 330
14.125 Phico Therapeutics Ltd. 331
14.125.1 Technology 331
14.125.2 Products 331
14.125.2.1 SASPject PT1.2 331
14.125.2.2 SASPject PT3.1 331
14.125.2.3 SASPject PT4 331
14.126 PolyActiva Pty Ltd. 332
14.126.1 Drug Delivery Platform 332
14.126.2 Glaucoma Program 333
14.126.3 Endophthalmitis 333
14.126.4 Osteoarthritis Program 333
14.127 PolyMicrospheres 333
14.128 PolyTherics Ltd. 334
14.128.1 ThioBridge 334
14.128.2 TheraPEG 334
14.128.3 HiPEG 335
14.128.4 CyPEG 335
14.128.5 PolyPEG 335
14.129 Presage Biosciences Inc. 335
14.129.1 CIVO Platform 335
14.130 pSivida Corp. 336
14.130.1 Durasert Technology 336
14.130.2 pSivida's Product Pipeline 336
14.130.3 Iluvien 337
14.130.4 Retisert 337
14.130.5 Durasert/Latanoprost 337
14.131 Pulmatrix Inc. 338
14.131.1 iSPERSE 338
14.131.2 PUR1900 338
14.131.3 PUR1500 338
14.131.4 PUR0200 339
14.132 Quark Pharmaceuticals Inc. 339
14.132.1 Quark's siRNA Technology Platform 339
14.133 Ra Pharmaceuticals Inc. 340
14.133.1 RA101495 341
13.133.2 Factor D Inhibitor 341
14.134 RaNA Therapeutics Inc. 341
14.135 RegeneRx Biopharmaceuticals Inc. 342
14.135.1 T?4 Peptide Research 342
14.136 Regenxbio Inc. 343
14.136.1 NAV Technology 343
14.137 Renova Therapeutics Inc. 344
14.138 Replicor Inc. 344
14.138.1 NAP Technology 344
14.138.2 Replicor's Pipeline 345
14.138.2.1 Phase II Proof of Concept Clinical Study Pipeline 345
14.138.3 Replicor's Regulatory Pipeline 346
14.139 RetroSense Therapeutics LLC 346
14.139.1 RST-001 346
14.140 Rexahn Pharmaceuticals Inc. 346
14.140.1 Supinoxin (RX-5902) 347
14.140.2 RX-3117 347
14.140.3 Archexin 347
14.140.4 RX-21101 347
14.140.5 Archexin-Nano 347
14.141 RJS Biologics LLC 348
14.141.1 Technology 348
14.142 Roche Holding AG 349
14.142.1 Rocaltrol 349
14.142.2 Accutane 349
14.143 Sarfez Pharmaceuticals Inc. 349
14.144 Savara Inc. 350
14.145 Scintipharma Inc. 351
14.145.1 InteliSite Companion Capsule 351
14.146 Sequus Pharmaceuticals Inc. 351
14.146.1 Amphocil 351
14.146.2 Doxil 352
14.147 Serina Therapeutics Inc. 352
14.147.1 POZ Technology 352
14.147.2 Serina's Pipeline 353
14.148 Serpin Pharma LLC 354
14.148.1 SP16 354
14.149 Silence Therapeutics PLC 354
14.150 Silenseed Ltd. 355
14.150.1 The LODER Platform 355
14.151 Sylentis SA 355
14.151.1 Bamosiran 356
14.151.2 SYL 1001 356
14.152 SoluBest Ltd. 356
14.152.1 Solumer Technology 357
14.152.2 Sepomer Technology 357
14.152.3 Contromer 357
14.152.4 Advanced Stage Products 357
14.152.5 Fenofibrate 357
14.152.6 Albendazole 357
14.152.7 Resveratrol 357
14.152.8 Testosterone undecanoate 358
14.153 Spark Therapeutics 358
14.154 Spheringenics Inc. 359
14.154.1 Technology 359
14.155 Suda Ltd. 359
14.155.1 Technology 359
14.155.2 ZolpiMist: Insomnia 360
14.155.3 ArTiMist: Malayria 360
14.155.4 SUD-001: Migraine 360
14.155.5 SUD-002: Nausea 360
14.155.6 SUD-003: Erectile Dysfunction 360
14.155.7 SUD-004: Pulmonary Arterial Hypertension 360
14.155.8 SUD-005: Anxiety 360
14.156 Supratek Pharma Inc. 361
14.156.1 Biotransport Technology 361
14.156.2 CombiForm Toolbox 361
14.156.3 Product Pipeline 361
14.157 Taiwan Liposome Co. Ltd. 362
14.157.1 Technology 362
14.157.1.1 Nano-Emulsion 362
14.157.1.2 Polymeric Mycelle 362
14.157.1.3 NanoX 363
14.157.1.4 Immunoliposome 364
14.157.1.5 BioSeizer 364
14.157.2 Pipeline 364
14.157.2.1 Doxisome 364
14.157.2.2 Lipo-Dox 364
14.157.2.3 Lipotecan 365
14.157.2.4 TLC178 365
14.157.2.5 AmBiL 365
14.157.2.6 ProFlow 365
14.157.2.7 ProDex 365
14.157.2.8 TLC599 365
14.158 TheraSource LLC 366
14.158.1 rhMFG-E8 366
14.158.2 Ghrelin 366
14.158.3 AM/AMBP-1 366
14.159 Transgene SA 368
14.160 Valeant Pharmaceuticals International Inc. 368
14.160.1 Efudex 368
14.161 Vect-Horus S.A.S. 369
14.161.1 Technology 369
14.161.2 Vect-Horus' Scientific Collaboration with Servier 370
14.161.3 Vect-Horus' Scientific Collaboration with Servier 370
14.162 Vectura Group plc 370
14.162.1 PowderHale 370
14.162.2 ParticleMax 370
14.162.3 GyroHaler 371
14.162.4 Akita Jet 371
14.162.5 Akita Apixneb 371
14.162.6 Fox 371
14.163 Vical Inc. 372
14.163.1 Poloxamer Delivery System 372
14.163.2 Vaxfectin Adjuvant 372
14.164 Voyager Therapeutics Inc. 373
14.165 WAVE Life Sciences Pvt. Ltd. 374
14.165.1 Platform 374
14.166 Xel Pharmaceuticals 375
14.166.1 Xel's Proprietary Drug Delivery Technologies 375
14.166.2 Transdermal Delivery System 375
14.166.3 Topical Delivery System 375
14.166.4 Implant Delivery Systems 376
14.166.5 Oral Controlled Release 376
14.166.6 Effervescent Tablet/Lozenge 376
14.166.7 Cold Water Extraction 376
14.167 Xenetic Biosciences 377
14.167.1 Technologies 377
14.167.1.1 PolyXen 377
14.167.1.2 OncoHist 377
14.168 Xigen SA 378
14.168.1 Technology 378
14.169 Zealand Pharma AS 379
14.170 Zozano Pharma Corp. 379
14.170.1 ZP-PTH 380
14.170.2 Zozano's Product Pipeline 380

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
European Market Report for Peripheral Intravenous Catheters 2017 - MedCore

European Market Report for Peripheral Intravenous Catheters 2017 - MedCore

  • $ 6495
  • Industry report
  • November 2016
  • by iData Research, Inc.

Description The European PIVC market includes three segments: conventional PIVCs, safety PIVCs and midlines. The safety PIVC segment includes three sub-segments: active safety PIVCs, passive safety PIVCs ...

North American Drug Delivery Technologies Market by Route of Administration, Pulmonary, Injectable, Ocular, Nasal, Topical, Implantable), End User - Global Forecast to 2021

North American Drug Delivery Technologies Market by Route of Administration, Pulmonary, Injectable, Ocular, Nasal, Topical, Implantable), End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • August 2016
  • by MarketsandMarkets

The North American drug delivery technologies market is projected to reach USD 758.7 billion by 2021 from USD 520.0 billion in 2016, at a CAGR of 6.5% during the forecast period. Major factors contributing ...

Syringes Market by Usability & Disposable Syringes), Material, Type - Global Forecast to 2021

Syringes Market by Usability & Disposable Syringes), Material, Type - Global Forecast to 2021

  • $ 5650
  • Industry report
  • November 2016
  • by MarketsandMarkets

The syringes market is expected to reach USD 15.99 billion by 2021, at a CAGR of 8.7% from 2016 to 2021. The syringes market is primarily driven by the high prevalence of chronic diseases across the globe. ...

Global Polymeric Foams Industry

October 2016 $ 4950

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.